UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
FORM 15

 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
 
Commission File Number: 001-35921
 

MIRATI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

3545 Cray Court,
San Diego, California 92121
Telephone: (858) 332-3410
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
 
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)


 Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
Rule 12g-4(a)(1)
☒
Rule 12g-4(a)(2)
☐
Rule 12h-3(b)(1)(i)
☒
Rule 12h-3(b)(1)(ii)
☐
Rule 15d-6
☐
Rule 15d-22(b)
☐
 
Approximate number of holders of record as of the certification or notice date: One holder
 
Pursuant to the requirements of the Securities Exchange Act of 1934, Mirati Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: February 2, 2024
Mirati Therapeutics, Inc.




By:
/s/ Kimberly Jablonski

Name:
Kimberly Jablonski

Title:
Vice President and Secretary


Mirati Therapeutics (NASDAQ:MRTX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Mirati Therapeutics.
Mirati Therapeutics (NASDAQ:MRTX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Mirati Therapeutics.